Himen Salimizand - Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Saeid Amel Jamehdar - Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Leila Babaei Nik - Tuberculosis Reference Center, Dr Shariati Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Hamid Sadeghian - Antimicrobial Resistance Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Objective(s): Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis (Mtb), stayed a global health thread with high mortality rate. Since TB has a long-term treatment, it leads high risk of drug resistant development, and there is an urgent to find new drugs. The aim of this study was designing new inhibitors for a new drug target, iron dependent regulator, IdeR. Materials and Methods: Based on the interaction most populated amino acids of IdeR to the related gene operators, ۵۰ short peptides were modeled. Bonding affinity of short peptides toward DNA were studied by docking. Top ۱۰ best predicted bonding affinity were selected. DNA binding assay, microplate alamar blue assay, colony counting, quantitative real time- PCR (qRT-PCR) of IdeR corresponding genes, cell wall-associated mycobactin and whole-cell iron estimation were done to prove the predicted mechanism of in silico potent constructs. Results: Amongst the ۱۰ synthesized short peptide candidates, glycine-valine-proline-glycine (GVPG) and arginine-proline-arginine (RPR) inhibited Mtb in vitro at ۲۰۰ µM concentration. qRT-PCR showed mbtB ۵۸-fold over expression that resulted in Mtb growth inhibition. Cell wall-associated mycobactin and whole-cell iron estimation confirmed the results of qRT-PCR. Conclusion: We introduced two new lead compounds to inhibit Mtb that are promising for the development of more potent anti-tubercular therapies.

IdeR, Inhibitor, Modeling, Mycobacterium tuberculosis, RT-PCR